– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare

– Interim results from HALO, a Phase 4 study of hyaluronic acid (HA) injectables in adults on GLP-1 medications, showed high patient satisfaction, with 95.7% of participants satisfied or very satisfied that they still looked like themselves

– The findings are part of a broad Allergan Aesthetics scientific program at ASDS 2026, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation and skin quality

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.